Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02024204 · ClinicalTrials.gov registry record · NA
Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT02024204 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 60 participants.
The verdict
NCT02024204, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to understand why patients in the World Trade Center program have continuing breathing problems. This study will improve investigators understanding of breathing problems among individuals with World Trade Center exposure by allowing them to review and monitor medication use, lung function, and examine other conditions that can contribute to problems with breathing. The findings from the study will help investigators understand why some people have persistent lower respiratory symptoms (breathing problems) after their exposure to World Trade Center dust and fumes, and may help guide better management and treatment of these symptoms.
Interventions
- DRUG Fluticasone propionate 230mcg for 3 Months
- DRUG Current Treatment or no treatment
- DRUG Salmeterol 21mcg for 3 Months
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-04-09 |
| Est. Completion | 2017-05-17 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02024204
The ClinicalTrials.gov registry entry for NCT02024204 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluticasone propionate 230mcg for 3 Months is the first listed.
NCT02024204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02024204 about?
NCT02024204 is a clinical study titled "Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program". The purpose of this study is to understand why patients in the World Trade Center program have continuing breathing problems. This study will improve investigators understanding of breathing problems among individuals with World Trade Center exposure by allowing them to review and monitor medication...
What is the current status of trial NCT02024204?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2014-04-09. Estimated completion is 2017-05-17.
What interventions are being tested in trial NCT02024204?
The interventions under investigation include: Fluticasone propionate 230mcg for 3 Months (DRUG), Current Treatment or no treatment (DRUG), Salmeterol 21mcg for 3 Months (DRUG).
Who is sponsoring clinical trial NCT02024204?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.